Skip to content
Precision for Medicine
Contact Us
clinical-sample-kitting (1)

Custom Clinical Kitting Services

For Complex and Precision Medicine Trials

Integrating biomarker strategies with clinical operations to ensure sample integrity and regulatory compliance

In early-phase precision medicine trials, every sample holds significant value. Precision for Medicine specializes in bespoke kitting solutions that not only ensure accurate sample collection but also uphold the highest standards of regulatory compliance. Our blend of automation and human expertise allows us to adapt swiftly to the evolving needs of your trial, ensuring that your research progresses seamlessly.

Precision's newly updated facilities in Frederick, Maryland and Berlin, Germany provide global coverage, offering a reliable kitting partner with an approach designed to fit the specific needs of early-phase clinical trial kitting projects.

Key Differentiators

  • 01 icon-1

    Adaptive Kitting Strategies

    Tailored to meet the specific requirements of early-phase precision medicine trials.
  • 02 icon-1

    Regulatory Compliance

    Ensuring that all processes align with the latest industry standards and guidelines.
  • 03 icon-1

    Integrated Ecosystem

    Leveraging comprehensive expertise to support every phase of your trial.
  • 04 icon-1

    Enhanced Capabilities

    Our Frederick, MD and Berlin, Germany location enhancements improve our ability to manage intricate trial demands.

Explore How We Deliver Smarter Kitting

Discover how our tailored kitting solutions support complex clinical trials. Take a look at both a quick overview of our global capabilities and an in-depth case study on how Precision kitting enabled a cell therapy trial with complex requirements. 

 Explore more Resources

Precision’s kitting, sample collection, and logistics services provide:

kit tubes

Kitting development and supply management

  • Trial and visit specific
  • Multiple sample types
  • Traceability of each component and expiry dates via 21CFR Part 11 compliant LIMS
  • Detailed kit status reporting
  • Sample collection training
Blood collection-1

Clinical site training

  • Collection-specific quality assurance plans
  • Development of training documentation
  • Competency and monitoring programs
global logistics-1

Logistics and transport management

  • Export/import permits
  • Late/evening shifts to receive deliveries and resolve shipment issues
  • Knowledge in planning best path for shipment
  • Ambient, refrigerated, or frozen shipment options
  • Experience with all major couriers—eg, QuickStat, World Courier, FedEx, Marken

Explore Precision’s other clinical logistics services

  • Explore
    PBMC
    sample-processing

    PBMC & Sample Processing

    Sample processing with expertise in PBMC isolations from labs across 5 continents

    Explore
    sample-processing

    PBMC & Sample Processing

    Sample processing with expertise in PBMC isolations from labs across 5 continents

    Explore
  • Explore
    biostorage_card-thumbnail
    biospecimens

    Biostorage

    Sample storage under all conditions and temperatures, rapid sample accessioning, and online inventory access

    Explore
    biospecimens

    Biostorage

    Sample storage under all conditions and temperatures, rapid sample accessioning, and online inventory access

    Explore
  • Explore
    LabEportal

    Precision Lab e-Portal

    Real-time visibility into project, sample, kit, and shipment status provides 24/7 access to critical study data
    Explore

    Precision Lab e-Portal

    Real-time visibility into project, sample, kit, and shipment status provides 24/7 access to critical study data
    Explore

Explore the Precision blog

Read our blog to gain more insights and discover work that Precision has supported.

Explore our blog
Read: Why Global Oncology Evidence May Not Support U.S. Regulatory Approval Why Global Oncology Evidence May Not Support U.S. Regulatory Approval

Clinical Trials - Regulatory

Why Global Oncology Evidence May Not Support U.S. Regulatory Approval

|
    has not third author: true, (SizeLimitingPyMap: {main={hs_id=167363064857, hs_child_table_id=0, hs_updated_at=1719905898183, hs_published_at=1785476963368, description=Industry-leading oncologist and demonstrated medical leader in precision medicine, novel trial design and innovative regulatory initiatives designed to expedite drug approvals. Draws on nearly a decade leading oncology and rare disease programs at the FDA. Former fellow at the National Cancer Institute and frequent featured speaker at ASCO and AACR. CDER technical authority on oncologic drug and biological products for thoracic and head and neck malignancies, neurologic tumors, pediatric solid tumors and rare tumors., avatar=Image{width=553,height=580,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/Headshots/Headshots%20no%20background/Harpreet-Singh2.png',altText='Harpreet-Singh2',fileId=171747124346}, linkedin=https://www.linkedin.com/in/harpreetsinghmd/, team=[{id=163072475007, name='Precision for Medicine Leadership'}], lastname=Singh, MD, hs_initial_published_at=1715692570942, hs_created_by_user_id=2737751, hs_created_at=1715692477118, hs_is_edited=false, hs_deleted_at=0, name=Harpreet, job=Chief Medical Officer, slug=harpreet-singh, hs_updated_by_user_id=65160865}, second={}, third={}})
  • Harpreet Singh, MD avatar

    Harpreet Singh, MD
Discover
Read: Early-Phase Oncology Trials in Ireland: Why START Dublin Is a High-Performing Site for Sponsors Early-Phase Oncology Trials in Ireland: Why START Dublin Is a High-Performing Site for Sponsors

Clinical Trials

Early-Phase Oncology Trials in Ireland: Why START Dublin Is a High-Performing Site for Sponsors

|
    has not third author: true, (SizeLimitingPyMap: {main={hs_id=164713188870, hs_child_table_id=0, hs_updated_at=1754641424769, hs_published_at=1785476963368, description=Deana Demjen is Director of the Precision Site Network, bringing nearly 20 years of clinical research to the role. Most of her previous experience has been in feasibility and site-identification. She has been covering a wide range of therapeutic areas, but her main focus are rare diseases where she is an acting subject matter expert. She is responsible for relationships with PSN sites as well as the maintenance and expansion of the network., avatar=Image{width=287,height=287,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/PfMxMarkentive/authors/Deana-Demjen-1.png',altText='Deana-Demjen-1',fileId=194123711869}, lastname=Demjen, hs_initial_published_at=1713363230550, hs_created_by_user_id=5166971, hs_created_at=1713363112834, hs_is_edited=false, hs_deleted_at=0, name=Deana, job=Director of PSN, slug=deana-demjen, hs_updated_by_user_id=65160865}, second={}, third={}})
  • Deana Demjen avatar

    Deana Demjen
Discover
Read: Receptor Occupancy in the Era of Multispecific Therapeutics Receptor Occupancy in the Era of Multispecific Therapeutics

Translational Research - Lab Services

Receptor Occupancy in the Era of Multispecific Therapeutics

|
    has not third author: true, (SizeLimitingPyMap: {main={hs_id=159488778875, hs_child_table_id=0, hs_updated_at=1716454216458, hs_published_at=1785476963368, description=Pharma industry veteran and expert at biomarker-driven clinical trial design and execution. Leader of biomarker and drug development programs for pharmaceutical and diagnostics companies, as well as the National Institutes of Health. Spearheaded the discovery of pharmacodynamic biomarkers and novel targets for inflammatory disease therapy., avatar=Image{width=576,height=576,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/Headshots/Headshots%20no%20background/Deb%20Phippard.webp',altText='Deb Phippard',fileId=165892372605}, linkedin=https://www.linkedin.com/in/deb-phippard-103b54, team=[{id=163072475007, name='Precision for Medicine Leadership'}], hs_name=, hs_path=, lastname=Phippard, PhD, hs_initial_published_at=1775839468505, hs_created_at=1709645745106, hs_is_edited=false, hs_deleted_at=0, name=Deborah, job= Chief Scientific Officer, slug=deborah-phippard, email=, hs_updated_by_user_id=65160865}, second={hs_id=218178874459, hs_child_table_id=0, hs_updated_at=1785241362455, hs_published_at=1785476963368, description=Jenny Zilberberg has more than 20 years of combined experience across academia and biotechnology, with expertise in translational immunology, cancer immunotherapy, and biomarker strategy. Most recently, she served as Head of Research at Imvax, where she led preclinical development and biomarker activities for the company’s immunotherapy platform and lead glioblastoma program. At Precision, Jenny partners with sponsors to design and implement biomarker and bioanalytical solutions that support clinical development across oncology and autoimmune diseases., avatar=Image{width=480,height=480,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/JennyZilberberg.jpeg',altText='JennyZilberberg',fileId=218182303073}, lastname=Zilberberg, hs_initial_published_at=1785241367324, hs_created_by_user_id=65712240, hs_created_at=1785241302354, hs_is_edited=false, hs_deleted_at=0, name=Jenny, job=Vice President, Scientific Strategy, slug=Jenny-zilberberg, hs_updated_by_user_id=65160865}, third={}})
  • Deborah P. avatar

    Deborah P.
  • Jenny Z. avatar

    Jenny Z.
Discover
Loading...